**3. Future Directions for Next Generation oHSVs**

Currently, more than 20 clinical trials on already tested, but newly developed HSV-1 related OVs are also underway (Table 2). Further studies on known compounds such as G207, HF10, and T-Vec are designed to determine safety and tolerability for either different malignancies or combinations with chemotherapy (NCT03252808, NCT02779855, NCT03300544, NCT03554044), radiotherapy (NCT03911388, NCT04482933, NCT03300544, NCT02923778), or checkpoint inhibition (NCT03153085, NCT04185311, NCT02978625, NCT02965716, NCT04163952).

Newly developed candidates include G47∆, rQNestin, M032, RP1, RP2, Rrp450, ONCR-177, and C134. As many of the initial trials had shown safety but no efficacy as described above, subsequent trials were designed to answer remaining questions.


**Table 2.** Outlook on ongoing and future clinical trials on oncolytic Herpes viruses.






